When will toviaz be generic?

When does Toviaz (fesoterodine) lose exclusivity?

Toviaz’s time frame for a first generic entry depends on when relevant patents and related exclusivity end for the product and its active ingredient (fesoterodine). Patent and exclusivity dates can vary by country and by which patent is the last to expire.

DrugPatentWatch tracks these dates and updates them as filings and court outcomes change. You can check the latest status here: DrugPatentWatch – Toviaz (fesoterodine).

What “generic time” can mean (patent vs. actual launch)

Even if a drug’s patents expire, a generic usually launches only after:
- the applicable exclusivity period ends, and/or
- any patent litigation is resolved (or a manufacturer gets authorization to launch), and
- regulators approve the abbreviated application for the generic.

That means the “earliest possible generic” date can be earlier than the “first generic actually on shelves” date.

Can generics arrive right after the last patent expires?

Sometimes, but not always. If a company faces ongoing patent challenges, the court outcome can delay launch even after one or more patents expire. DrugPatentWatch is useful for seeing whether there are listed patents, expected expiry windows, and whether other events could affect timing: DrugPatentWatch – Toviaz (fesoterodine).

Which country are you asking about?

Generic availability timing differs a lot by market (US vs. EU vs. UK vs. Canada, for example). If you tell me the country (or where you buy Toviaz), I can narrow the answer to the most relevant expiry/exclusivity timeline for that specific jurisdiction.

Sources

1. DrugPatentWatch – Toviaz (fesoterodine)